About Lundbeck

Lundbeck is a global pharmaceutical company specialising exclusively in brain diseases. With more than 70 years of neuroscience expertise, the company has developed and commercialised widely prescribed therapies for conditions including depression, schizophrenia, Parkinson's disease and migraine. Its products are registered in over 80 countries and reach approximately 28 million people worldwide. The company operates across the full pharmaceutical value chain from research to distribution. Headquartered in Copenhagen, Denmark, Lundbeck employs approximately 5,300 people globally. As a publicly traded company majority owned by the Lundbeck Foundation, it invests significantly in neuroscience research while maintaining a patient centred approach.